LivaNova plc (LIVN): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

LivaNova PLC enjoys global recognition for its development of neurostimulators and cardiac equipment, leveraging an expansion strategy for vagus nerve stimulation systems. Tracking the business's EV/EBITDA multiple history on GURU.Markets, we note that the 16.13 level reflects the current state of the parameter. High barriers to entry are sustained by FDA patents and the unwavering trust of surgeons in the brand's clinical outcomes.

LivaNova Group - LIVN Company Value to EBITDA (period 11/23/2025 - 11/13/2026)

Metric breakdowns and analytics for livanova.com (LIVN)

- current price and projected stock value:

Stock Price LivaNova Group|LIVN - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value LivaNova Corp|LIVN - Business Value

- book value of equity indicators:

Book Value per Share LivaNova|LIVN - Total Stockholders' Equity|Market Value to Book Value Ratio livanova.com|LIVN - Company Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

LIVN - Company Net Income|Projected Future Earnings LivaNova PLC|LIVN - Price to Earnings Multiple|Forward P/E Multiple LivaNova PLC|LIVN - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple LivaNova Corp|LIVN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) LivaNova|LIVN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months livanova.com|LIVN - Earnings per share growth in current year|Expected earnings per share growth for next year LivaNova PLC

Comprehensive company analysis:LivaNova Group (LIVN)

This ratio correlates the total enterprise value, including net debt, with operating profit before depreciation and amortization, allowing for an assessment of the asset's real value regardless of the tax burden. The current EV/EBITDA value for the heavy business segment stands at 16.13, which, combined with full capacity utilization at LivaNova PLC (LIVN) plants and the modernization of production lines, confirms the efficiency of cash flow generation despite high capital intensity.

Key competitors

EV/EBITDA Multiple SYK (Stryker Inc)|EV/EBITDA Multiple Medtronic Corp MDT|PHG - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNN (smith-nephew.com) - Enterprise Value to Operating Income Before Depreciation|HOLX: EV/EBITDA Multiple|Company Value to EBITDA Carlisle Companies Incorporated (CSL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Greatbatch|Company Value to EBITDA AdaptHealth Inc. AHCO|Enterprise Value to EBITDA Ratio SSII (SS Innovations)|EV/EBITDA Multiple avanos.com (AVNS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shoulder Innovations SI|Total Company Value to Operating Income Before Depreciation Ratio Viemed Healthcare (VMD)|INGN: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation OWLT (Owlet, Inc.)|Quipt Home Medical (QIPT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Precision Optics Corporation|PAVM (PAVmed, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Tivic Health Systems, Inc. TIVC|EV/EBITDA Multiple MOVE|Nuvo Group Ltd - Enterprise Value to Operating Income Before Depreciation